A Systems Biology Perspective on the Molecular Mechanisms Underlying the Therapeutic Effects of Buyang Huanwu Decoction on Ischemic Stroke

Rejuvenation Research

Volumn 18, Issue 4, 2015, Pages 313-325

  Guo, Qiuyan ^a   Zhong, Micun ^a   Xu, Haiyu ^a   Mao, Xia ^a   Zhang, Yanqiong ^a   Lin, Na ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICA ROOT; ASTRAGALUS ROOT; BUYANG HUANWU; CHINESE DRUG; HERBACEOUS AGENT; LIGUSTICUM CHUANXIONG EXTRACT; NEUROTROPHIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PAEONIA RADIX; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BRAIN ISCHEMIA; CALCIUM SIGNALING; CHEMICAL COMPOSITION; CHINESE MEDICINE; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFORMATION RETRIEVAL; MOLECULAR DOCKING; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SMOOTH MUSCLE CONTRACTION; SYSTEMS BIOLOGY; THERAPY EFFECT; VASCULAR SMOOTH MUSCLE; COMPLICATION; MOLECULARLY TARGETED THERAPY; STROKE;

BRAIN ISCHEMIA; DRUGS, CHINESE HERBAL; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN INTERACTION MAPS; STROKE; SYSTEMS BIOLOGY;

EID: 84939814453     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2014.1635     Document Type: Review

References (62)

1. Manning NW, Campbell BC, Oxley TJ, Chapot R. Acute ischemic stroke: Time, penumbra, and reperfusion. Stroke 2014;45:640-644.
2. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J 2013;77:1923-1932.
3. Singh P, Kaur R, Kaur A. Endovascular treatment of acute ischemic stroke. J Neurosci Rural Pract 2013;4:298-303.
4. Tymianski M. Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke 2013;44:2942-2950.
5. Chen YF. Traditional Chinese herbal medicine and cerebral ischemia. Front Biosci (Elite Ed) 2012;4:809-817.
6. Sucher NJ. Insights from molecular investigations of traditional Chinese herbal stroke medicines: Implications for neuroprotective epilepsy therapy. Epilepsy Behav 2006;8: 350-362.
7. Xian-Hui D, Xiao-Ping H, Wei-Juan G. Neuroprotective effects of the Buyang Huanwu decoction on functional recovery in rats following spinal cord injury. J Spinal Cord Med 2014; in press.
8. Liu B, Cai G, Yi J, Chen X. Buyang Huanwu Decoction regulates neural stem cell behavior in ischemic brain. Neural Regen Res 2013;8:2336-2342.
9. Li JH, Liu AJ, Li HQ, Wang Y, Shang HC, Zheng GQ. Buyang huanwu decoction for healthcare: Evidencebased theoretical interpretations of treating different diseases with the same method and target of vascularity. Evid Based Complement Alternat Med 2014;2014:506783.
10. Wang L, Huang Y, Wu J, Lv G, Zhou L, Jia J. Effect of Buyang Huanwu decoction on amino acid content in cerebrospinal fluid of rats during ischemic/reperfusion injury. J Pharm Biomed Anal 2013;86:143-150.
11. Shen J, Zhu Y, Yu H, Fan ZX, Xiao F, Wu P, Zhang QH, Xiong XX, Pan JW, Zhan RY. Buyang Huanwu decoction increases angiopoietin-1 expression and promotes angiogenesis and functional outcome after focal cerebral ischemia. J Zhejiang Univ Sci B 2014;15:272-280.
12. Kong X, Su X, Zhu J, Wang J, Wan H, Zhong M, Li L, Lin N. Neuroprotective effect of buyang huanwu decoction on rat ischemic/reperfusion brain damage by promoting migration of neural precursor cells. Rejuvenation Res 2014; 17:264-275.
13. Wang L, Jiang DM. Neuroprotective effect of Buyang Huanwu Decoction on spinal ischemia-reperfusion injury in rats is linked with inhibition of cyclin-dependent kinase 5. BMC Complement Altern Med 2013;13:309.
14. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008;4:682-690.
15. Liang X, LiH, Li S. A novel network pharmacology approach to analyse traditional herbal formulae: The Liu-Wei-Di-Huang pill as a case study. Mol Biosyst 2014;10:1014-1022.
16. Tao W, Xu X, Wang X, Li B, Wang Y, Li Y, Yang L. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 2013;145:1-10.
17. Liu ZH, Sun XB. Network pharmacology: New opportunity for the modernization of traditional Chinese medicine. Yao Xue Xue Bao 2012;47:696-703.
18. Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One 2010;5:e11764.
19. Li S, Zhang B, Zhang NB. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Systems Biol 2011;5:S10.
20. Li S, Zhang B, Jiang D, Wei YY, Zhang NB. Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formula. BMC Bioinformatics 2010; 11(Suppl):S6.
21. Chen CY-C. TCM Database@Taiwan: The world's largest traditional Chinese medicine database for drug screening in silico. PLoS One 2011;6:e15939.
22. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901-D906.
23. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 2005; 33(Database Issue):D514-D517
24. Chen JY, Mamidipalli S, Huan T. HAPPI: An online database of comprehensive human annotated and predicted protein interactions. BMC Genomics 2009;10(Suppl 1):S16.
25. D'Eustachio P. Reactome knowledgebase of human biological pathways and processes. Methods Mol Biol 2011; 694:49-61.
26. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics 2005;21:2076-2082.
27. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, Derow C, Feuermann M, Ghanbarian AT, Kerrien S, Khadake J, Kerssemakers J, Leroy C, Menden M, Michaut M, Montecchi-Palazzi L, Neuhauser SN, Orchard S, Perreau V, Roechert B, van Eijk K, Hermjakob H. The IntAct molecular interaction database in 2010. Nucleic Acids Res 2010;38:D525-D531.
28. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. Human Protein Reference Database-2009 update. Nucleic Acids Res 2009;37:D767-D772.
29. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, Perfetto L, Castagnoli L, Cesareni G. MINT, the Molecular Interaction Database: 2009 update. Nucleic Acids Res 2010;38:D532-D539.
30. Lehne B, Schlitt T. Protein-protein interaction databases: Keeping up with growing interactomes. Hum Genomics 2009;3:291-297.
31. Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H. PDZBase: A protein-protein interaction database for PDZ-domains. Bioinformatics 2005;21:827-828.
32. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang J, Han B, Zhang P, Chen Y. Therapeutic target database update 2012: A resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2012; 40(database issue): D1128-D1136.
33. Zsoldos Z, Reid D, Simon A, Sadjad BS, Johnson AP. eHiTS: An innovative approach to the docking and scoring function problems. Curr Protein Pept Sci 2006;7: 421-435.
34. Rose PW, Prlić A, Bi C, Bluhm WF, Christie CH, Dutta S, Green RK, Goodsell DS, Westbrook JD, Woo J, Young J, Zardecki C, Berman HM, Bourne PE, Burley SK. The RCSB Protein Data Bank: Views of structural biology for basic and applied research and education. Nucleic Acids Res 2015;43(database issue):D345-D356.
35. Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, LeBlanc E, Guns ET, Guy RK, Rennie PS, Cherkasov A. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem 2011;54:8563-8573.
36. Axerio-Cilies P, Lack NA, Nayana MR, Chan KH, Yeung A, Leblanc E, Guns ES, Rennie PS, Cherkasov A. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. J Med Chem 2011; 54:6197-6205.
37. Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001;411:41-42.
38. Penrod NM, Moore JH. Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics. BMC Syst Biol 2014;8:12.
39. Wang Y, Liu Z, Li C, Li D, Ouyang Y, Yu J, Guo S, He F, Wang W. Drug target prediction based on the herbs components: The study on the multitargets pharmacological mechanismof qishenkeli acting on the coronary heart disease. Evid Based Complement Alternat Med 2012;2012:698531.
40. Zhang Y, Guo X, Wang D, Li R, Li X, Xu Y, Liu Z, Song Z, Lin Y, Li Z, Lin N. A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci Rep 2014;4:4154.
41. Zhang Y, Li Z, Yang M, Wang D, Yu L, Guo C, Guo X, Lin N. Identification of GRB2 and GAB1 coexpression as an unfavorable prognostic factor for hepatocellular carcinoma by a combination of expression profile and network analysis. PLoS One 2013;8:e85170.
42. Zhang Y, Guo X, Yang M, Yu L, Li Z, Lin N. Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation. Mol Biosyst 2014;10:215-222.
43. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
44. Wixon J, Kell D. The Kyoto Encyclopedia of Genes and Genomes-KEGG. Yeast 2000;17:48-55.
45. Zhang Y, Wang D, Tan S, Xu H, Liu C, Lin N. A systems biology-based investigation into the pharmacological mechanisms of Wu Tou Tang acting on rheumatoid arthritis by integrating network analysis. Evid Based Complement Alternat Med 2013;2013:548498.
46. Nordahl H, Osler M, Frederiksen BL, Andersen I, Prescott E, Overvad K, Diderichsen F, Rod NH. Combined effects of socioeconomic position, smoking, and hypertension on risk of ischemic and hemorrhagic stroke. Stroke 2014;45: 2582-2587.
47. Hung CY, Wang KY, Wu TJ, Hsieh YC, Huang JL, Loh E-W, Lin CH. Resistant hypertension, patient characteristics, and risk of stroke. PLoS One 2014;9:e104362.
48. De Silva TM, Brait VH, Drummond GR, Sobey CG, Miller AA. Nox2 oxidase activity accounts for the oxidative stress and vasomotor dysfunction in mouse cerebral arteries following ischemic stroke. PLoS One 2011;6: e28393.
49. Skalidi SJ, Manios ED, Stamatelopoulos KS, Barlas G, Michas F, Toumanidis ST, Vemmos KN, Zakopoulos NA. Brain edema formation is associated with the time rate of blood pressure variation in acute stroke patients. Blood Press Monit 2013;18:203-207.
50. Pham M, Stoll G, Nieswandt B, Bendszus M, Kleinschnitz C. Blood coagulation factor XII-a neglected player in stroke pathophysiology. J Mol Med (Berl) 2012;90:119-126.
51. Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: Current status and challenges. Pharmacol Ther 2015;146:23-34.
52. Wang M, Yang H, Zheng LY, Zhang Z, Tang YB, Wang GL, Du YH, Lv XF, Liu J, Zhou JG, Guan YY. Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation. Circulation 2012;125:697-707.
53. Povlsen GK, Waldsee R, Ahnstedt H, Kristiansen KA, Johansen FF, Edvinsson L. In vivo experimental stroke and in vitro organ culture induce similar changes in vasoconstrictor receptors and intracellular calcium handling in rat cerebral arteries. Exp Brain Res 2012;219:507-520.
54. Yang AL, Liang QH, Cui HJ, Zhou HJ, Luo JK, Tang T. Angiogenesis opens a way for Chinese medicine to treat stroke. Chin J Integr Med 2013;19:815-819.
55. Adamczak JM, Schneider G, Nelles M, Que I, Suidgeest E, van der Weerd L, Löwik C, Hoehn M. In vivo bioluminescence imaging of vascular remodeling after stroke. Front Cell Neurosci 2014;8:274.
56. Wu L, Jiang Y, Zhu J, Wen Z, Xu X, Xu X, Xie Y, Yang L, Xu L, Lan W, Xu G, Liu X. Orosomucoid1: Involved in vascular endothelial growth factor-induced blood-brain barrier leakage after ischemic stroke in mouse. Brain Res Bull 2014;109:88-98.
57. Abais JM, Xia M, Li G, Chen Y, Conley SM, Gehr TW, Boini KM, Li PL. Nod-like receptor protein 3 (NLRP3) inflammasome activation and podocyte injury via thioredoxin-interacting protein (TXNIP) during hyperhomocysteinemia. J Biol Chem 2014;289:27159-27168.
58. Trendelenburg G. Molecular regulation of cell fate in cerebral ischemia: Role of the inflammasome and connected pathways. J Cereb Blood Flow Metab 2014;34:1857-1867.
59. Ishrat T, Mohamed IN, Pillai B, Soliman S, Fouda AY, Ergul A, El-Remessy AB, Fagan SC. Thioredoxin-inter-acting protein: A novel target for neuroprotection in experimental thromboembolic stroke in mice. Mol Neurobiol. 2015;51:766-778.
60. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2005;2:120-128.
61. Alhusban A, Kozak A, Ergul A, Fagan SC. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther 2013;344:348-359.
62. Han J, Pollak J, Yang T, Siddiqui MR, Doyle KP, Taravosh-Lahn K, Cekanaviciute E, Han A, Goodman JZ, Jones B, Jing D, Massa SM, Longo FM, Buckwalter MS. Delayed administration of a small molecule tropomyosinrelated kinase B ligand promotes recovery after hypoxicischemic stroke. Stroke 2012;43:1918-1924.